Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dex BTC restrictions?

This article was originally published in The Tan Sheet

Executive Summary

The Army & Air Force Exchange Service has adopted a voluntary plan prohibiting the sale of dextromethorphan (DXM) products to those under the age of 18, the AAFES announces Feb. 9. The policy, enacted Jan. 24, is designed to prevent teenagers from using the drug for recreational purposes. Military members can still purchase DXM products such as Wyeth's Robitussin andAdams' Mucinex over-the-counter at Base Exchange/Post Exchange stores, but will have to show proof of age at check-out. Walgreens enacted a similar nationwide policy in July 2005 in response to an FDA "Talk Paper" highlighting DXM abuse (1"The Tan Sheet" July 4, 2005 p. 12)...

You may also be interested in...

Walgreens Sets Dextromethorphan Age Limit Policy To Curb Abuse

Retailers are working to stay ahead of state legislators looking to place restrictions on products containing the cough suppressant ingredient dextromethorphan (DXM)

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts